| http://www.w3.org/ns/prov#value | - Matell H, Lycke J, Svenningsson A, Holm??n C, Khademi M, Hillert J, Olsson T, Piehl F. Abstract BACKGROUND: Natalizumab is approved for treatment of active forms of relapsing-remitting multiple sclerosis (MS) based on a pivotal phase III study comprising patients aged 18-50 years.
|
